There are currently several reputable
guidelines on the treatment of actinic keratosis (AK) from groups in Canada, the United Kingdom, and Europe. These recommendations, based on evidence or expert
consensus, offer clinicians a variety of treatment options for the different clinical presentations of AKs. Although the
guidelines are similar in some regards, variations exist in treatment options, duration, and strength of recommendation. Some
guidelines also lack input on specific therapies and certain types of AK, such as hypertrophic or thin presentations. The purpose of this article is to review and compare
guidelines published by Canadian, UK, and European groups for the management of AKs in patients.